TLRY Fundamental Analysis - TILRAY BRANDS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to TLRY. TLRY was compared to 35 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
In the past year TLRY has reported a negative cash flow from operations.
TLRY had negative earnings in each of the past 5 years.
In the past 5 years TLRY reported 4 times negative operating cash flow.

1.2 Ratios

TLRY's Return On Assets of -103.13% is on the low side compared to the rest of the industry. TLRY is outperformed by 82.86% of its industry peers.
The Return On Equity of TLRY (-139.41%) is worse than 74.29% of its industry peers.

		Industry Rank	Sector Rank
ROA	-103.13%
ROE	-139.41%
ROIC	N/A

ROA(3y)-48.32%

ROA(5y)-36.47%

ROE(3y)-65.2%

ROE(5y)-55.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TLRY has a Gross Margin of 28.69%. This is comparable to the rest of the industry: TLRY outperforms 45.71% of its industry peers.
In the last couple of years the Gross Margin of TLRY has grown nicely.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	28.69%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.36%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLRY has more shares outstanding than it did 1 year ago.
TLRY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.52, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TLRY (-1.52) is worse than 62.86% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that TLRY is not too dependend on debt financing.
The Debt to Equity ratio of TLRY (0.18) is better than 62.86% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Altman-Z	-1.52

ROIC/WACCN/A

WACC8.2%

2.3 Liquidity

TLRY has a Current Ratio of 2.62. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY has a Current ratio of 2.62. This is in the better half of the industry: TLRY outperforms 68.57% of its industry peers.
A Quick Ratio of 1.56 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY has a Quick ratio of 1.56. This is in the better half of the industry: TLRY outperforms 68.57% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.62
Quick Ratio	1.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for TLRY have decreased strongly by -379.00% in the last year.
Looking at the last year, TLRY shows a small growth in Revenue. The Revenue has grown by 4.10% in the last year.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.

EPS 1Y (TTM)-379%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%59%

Revenue 1Y (TTM)4.1%

Revenue growth 3Y9.34%

Revenue growth 5Y37.52%

Sales Q2Q%3.11%

3.2 Future

Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.45% on average per year.
The Revenue is expected to grow by 4.41% on average over the next years.

EPS Next Y96.64%

EPS Next 2Y40.72%

EPS Next 3Y25.89%

EPS Next 5Y15.45%

Revenue Next Year3.65%

Revenue Next 2Y4.08%

Revenue Next 3Y4.24%

Revenue Next 5Y4.41%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

TLRY's Enterprise Value to EBITDA is on the same level as the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	25.89

4.3 Compensation for Growth

A more expensive valuation may be justified as TLRY's earnings are expected to grow with 25.89% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.72%

EPS Next 3Y25.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TLRY!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

TILRAY BRANDS INC

TSX:TLRY (1/14/2026, 7:00:00 PM)

13.75

+0.69 (+5.28%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)01-08 2026-01-08/amc

Earnings (Next)04-06 2026-04-06/bmo

Inst Owners11.21%

Inst Owner ChangeN/A

Ins Owners0.35%

Ins Owner ChangeN/A

Market Cap1.59B

Revenue(TTM)821.31M

Net Income(TTM)-2.15B

Analysts71.25

Price Target23.6 (71.64%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-2631.48%

Min EPS beat(2)-5362.97%

Max EPS beat(2)100%

EPS beat(4)1

Avg EPS beat(4)-1385.84%

Min EPS beat(4)-5362.97%

Max EPS beat(4)100%

EPS beat(8)2

Avg EPS beat(8)-708.23%

EPS beat(12)2

Avg EPS beat(12)-746.7%

EPS beat(16)4

Avg EPS beat(16)-606.4%

Revenue beat(2)1

Avg Revenue beat(2)-3.41%

Min Revenue beat(2)-7.23%

Max Revenue beat(2)0.41%

Revenue beat(4)1

Avg Revenue beat(4)-6.19%

Min Revenue beat(4)-13.28%

Max Revenue beat(4)0.41%

Revenue beat(8)1

Avg Revenue beat(8)-5.71%

Revenue beat(12)2

Avg Revenue beat(12)-3.59%

Revenue beat(16)2

Avg Revenue beat(16)-3.93%

PT rev (1m)-1.44%

PT rev (3m)1529.26%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-788.89%

EPS NY rev (1m)-913.34%

EPS NY rev (3m)-369.14%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-1.01%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.58%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.38
P/FCF	N/A
P/OCF	N/A
P/B	0.75
P/tB	1.51
EV/EBITDA	25.89

EPS(TTM)-19.94

EYN/A

EPS(NY)-0.42

Fwd EYN/A

FCF(TTM)-1.15

FCFYN/A

OCF(TTM)-0.73

OCFYN/A

SpS9.94

BVpS18.43

TBVpS9.12

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-103.13%
ROE	-139.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	28.69%
FCFM	N/A

ROA(3y)-48.32%

ROA(5y)-36.47%

ROE(3y)-65.2%

ROE(5y)-55.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.36%

GM growth 5YN/A

F-Score3

Asset Turnover0.4

Health

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Debt/EBITDA	6.5
Cap/Depr	30.45%
Cap/Sales	4.3%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.62
Quick Ratio	1.56
Altman-Z	-1.52

F-Score3

WACC8.2%

ROIC/WACCN/A

Cap/Depr(3y)21.23%

Cap/Depr(5y)65.01%

Cap/Sales(3y)3.68%

Cap/Sales(5y)7.53%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-379%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%59%

EPS Next Y96.64%

EPS Next 2Y40.72%

EPS Next 3Y25.89%

EPS Next 5Y15.45%

Revenue 1Y (TTM)4.1%

Revenue growth 3Y9.34%

Revenue growth 5Y37.52%

Sales Q2Q%3.11%

Revenue Next Year3.65%

Revenue Next 2Y4.08%

Revenue Next 3Y4.24%

Revenue Next 5Y4.41%

EBIT growth 1Y28.53%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year109.61%

EBIT Next 3Y28.42%

EBIT Next 5Y17.38%

FCF growth 1Y-688.1%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-258.17%

OCF growth 3YN/A

OCF growth 5YN/A

TILRAY BRANDS INC / TLRY.CA FAQ

Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?

ChartMill assigns a fundamental rating of 2 / 10 to TLRY.CA.

What is the valuation status for TLRY stock?

ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY.CA). This can be considered as Overvalued.

How profitable is TILRAY BRANDS INC (TLRY.CA) stock?

TILRAY BRANDS INC (TLRY.CA) has a profitability rating of 1 / 10.

TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TILRAY BRANDS INC / TLRY.CA FAQ

Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?

What is the valuation status for TLRY stock?

How profitable is TILRAY BRANDS INC (TLRY.CA) stock?